BioWorld

Feb. 1, 2002

CuraGen, Bayer Advance Four Compounds Through Screening

One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today) Read More

ViaCell Files For $115M IPO To Fund Clinical Trials, R&D

One Unfertilized Egg From Single Female Primate Donor Produced Broad Spectrum Of Progeny Cells

Digene Raises $15M Through Stock Sale To Acqua Wellington

AltaRex Reanalyzes OvaRex IIb Results, Reaches Significance

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...